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Abstract
Vaccination is traditionally considered as a measure addressed to infants and children. Indeed, in natural conditions, vaccine-preventable
infections are mainly spread at a young age. The implementation of routine and mass vaccination programmes has led to the eradication of
smallpox and to the elimination of poliomyelitis in many regions of the world, together with the control of once life-threatening diseases like
diphtheria and tetanus. In more recent times, the development of new generation vaccines and the changing epidemiological proﬁle of many
vaccine-preventable diseases have greatly changed the objectives and the target of today’s immunization strategies. The objective of this
article is to highlight and discuss the evolution of vaccination strategies from measures aimed at protecting children to a practice that is
needed throughout life. Adolescents and adults need immunization for several reasons: they may not have received the vaccines usually
administered in childhood; new vaccines tailored for adolescents and adults have become available; immunity acquired thanks to
immunization in childhood can fade; and older adults or those who are chronically ill are more susceptible to vaccine-preventable diseases
and to their complications. The changing demographic proﬁle of both industrialized countries and of countries in transition towards an
‘aging’ population, and the shift of several infectious diseases towards adulthood make it imperative that new infrastructures to deliver
vaccines and new investments in immunization are investigated. Such a change of perspective is needed both to preserve health and to
guarantee the sustainability of health systems.
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Background
Vaccination is traditionally considered as a measure that is
addressed to infants and children. In natural conditions,
vaccine-preventable infections are mainly spread at a young
age. The start of attendance at day-care centres, nurseries
and primary schools is usually the typical age of acquisition
of highly contagious infections transmitted directly or
indirectly through airborne droplets or by the faecal–oral
route.
The implementation of routine and mass vaccination
programmes has led to the eradication of smallpox and to
the elimination of poliomyelitis in many regions of the world,
together with the control of once life-threatening diseases like
diphtheria and tetanus.
In the last three decades, the development of new
technologies (like recombinant DNA and conjugation of
polysaccharides) to produce vaccines that were impossible
to obtain using the conventional cultural techniques, has
allowed the introduction of immunization programmes against
hepatitis B, Haemophilus inﬂuenzae b, and pneumococcal and
meningococcal diseases in many countries of the world. The
efforts of countries and international agencies to increase
vaccination coverage have produced notable results [1]. In
some cases, the positive effects on mortality are not limited to
the vaccine-preventable disease itself, but expand to fatalities
caused by other agents whose pathogenic effects, in natural
conditions, are increased by the vaccine-preventable infectious
disease. For instance, a 13% increase of global coverage against
measles obtained between 2000 and 2010 has translated into a
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c.74% reduction of measles mortality [2] and an indirect effect
on casualties due to pneumonia and diarrhoeal diseases.
In more recent times, the development of the latest
generation of vaccines and the new epidemiological proﬁle of
many vaccine-preventable diseases have greatly changed the
objectives and the target of today’s immunization strategies.
For instance, the availability of human papillomavirus (HPV)
vaccines prompted health authorities to plan and organize
universal immunization programmes aimed at a non-traditional
target for previous vaccination strategies, that of adolescents.
We also have innovative tools, like new pneumococcal and
herpes zoster vaccines, that we can use to preserve health and
quality of life in the elderly population, an increasingly
numerous target where preventive activities can substantially
contribute to the sustainability of healthcare systems.
On the other hand, the most affected age groups for
traditional vaccine-preventable diseases (i.e. measles) have
changed because of suboptimal coverage in children. Measles
has become mainly a disease of adolescents and adults in many
industrialized countries.
The objective of this article is to highlight and discuss the
evolution of vaccination strategies from measures aimed at
protecting children to a practice that is needed throughout life.
Priority Setting on Vaccination Programmes
and New Ways to Measure Immunization
Impact
In the past, the drivers behind the decision to introduce a
vaccination programme were mainly the number of deaths and
serious disease cases. Relatively few vaccines were available,
and pharmaco-economic evaluations were not needed,
because the advantage of vaccination was self-evident and
there was a preference for vaccination early in life. Parents
accepted vaccination almost invariably, and the costs con-
nected with vaccination programmes were low.
Since the beginning of the 21st century, the world of
vaccination has started to change: many new vaccines are in
line and the approach to their introduction is focused on
evidence-based prevention. However, the communication
landscape has changed dramatically, and, as a consequence of
the reduction of incidence of once threatening diseases thanks
to widespread vaccination, parents are more concerned by the
adverse reactions of vaccines than by the disease itself.
Vaccines have a higher technological content and higher costs,
at least in the ﬁrst years following their availability.
Also, the concept of vaccine-preventable diseases has
changed. Traditionally, the effect of vaccination was measured
as the reduction (usually in the short term) of deaths, serious
sequelae, complications and number of cases for well-
characterized acute diseases. Measurement of effects is
performed using standard surveillance methods (incidence,
hospitalizations, mortality rates, etc.), and the end objective of
vaccination programmes is frequently elimination or even
eradication of an infectious agent.
With the newly developed vaccines, the impact of vaccina-
tion strategies is less frequently only a direct effect, it is often
prolonged (vaccines like HPV, for instance, extend their effects
for many decades to come), and it is not only ‘medical’ and not
easily measurable, given the frequent impact on economics, on
social settings or quality of life [3]. As a consequence, methods
to measure the effects of an immunization programme need to
be adapted to the new scenario. For instance, for inﬂuenza, the
reduction of hospitalizations and of work absenteeism might
be more relevant than the simple decrease of disease cases; for
rotavirus diarrhoea, the impact on family disruption is among
the most relevant expected outcomes; for herpes zoster,
vaccination is expected to impact especially on quality of life
and on social disruption. In addition, there is a need for
surrogates of protection when the maximum expected beneﬁt
is delayed (as for HPV). In brief, we need to shift from the
concept of prevention of disease to that of prevention of
illness (also including consequences on social disruption,
resource use, protection of high-risk groups, family and
community members, and impact on work absenteeism).
The characteristics of our evaluation tools are also
changing: for surveillance purposes, it is advisable to intro-
duce and validate the most modern tests for the surveillance
of infections (nucleic acids testing, genotyping, sequencing,
etc.).
On the other hand, a complete evaluation of the most
relevant aspects of the introduction of a new vaccine (from an
epidemiological, economic, ethical, organizational and commu-
nicational point of view) is needed today and is included in the
broad concept of Health Technology Assessment (HTA) [4]. In
this new landscape, it is necessary to implement the evaluation
techniques of evidence-based prevention, not only through
meta-analysis and systematic revision of efﬁcacy and safety of
vaccines, but also by expanding a multidisciplinary approach
(together with mathematicians, demographists and econo-
mists) to develop dynamic models on the epidemiology of
disease and on the impact of new vaccination strategies. Since
HTA also includes considerations of acceptability and ethical
and economic issues, we need to explore new methods for the
surveillance of social wellness, quality of life and impact on
productivity. Last but not least, in a scenario of more attention
given to adverse events following vaccination than to the
diseases prevented by vaccines, we need to learn and
experience relevant communication skills.
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Vaccination at Adolescent Age
Adolescence is a period of life when vaccination is of special
importance, becauseof different and partly overlapping factors: a
continuing risk of disease (for instance, meningococcal menin-
gitis, tetanus), with a possible need for booster doses; an
epidemiological shift of disease incidence because of incomplete
immunization programmes in childhood (i.e. measles and
rubella); the forthcoming risk for some infections, due to the
beginning of sexual life or at-risk behaviours (smoking, drug
abuse) (for instance, HPV and hepatitis B). Moreover, adoles-
cence is also a sort of ‘ﬁlter age’ to verify immunity to infections
that might have a more serious outcome when contracted in
adulthood (like varicella, hepatitis A and again measles and
rubella).
The difﬁculty of reaching adolescents with an effective
vaccination offer lies mainly on the typical features of subjects
in this age group: increase of independence, risk behaviour and
concrete thinking, and decrease (or absence) of parental
inﬂuence, health worries and orientation to the future. In
addition, organizational issues (who is responsible and where
vaccines should be delivered) can be important [5].
Vaccination of Adults: the New Frontier
Vaccine-preventable infectious diseases have decreased in
childhood, but have increased their relative and absolute
importance in adulthood.
Today, adults need vaccinations for different reasons. (1)
They may not have received vaccines usually administered in
childhood. Vaccines have been progressively inserted into the
routine vaccination schedule, and high coverage is sometimes
not achieved for relatively long periods. For this reason,
present day adults may still be unprotected, for instance,
against tetanus, measles, rubella and other vaccine-preventable
infections. (2) New vaccines tailored for adults have become
available. For instance, the herpes zoster vaccine is speciﬁcally
designed to protect adults and the elderly against the most
dreadful consequence of shingles, i.e. post-herpetic neuralgia.
(3) Immunity acquired thanks to immunization in childhood can
fade. A typical example is represented by pertussis, which
induces a non-permanent immunity both after natural infection
and after vaccination, for which reason, periodical booster
doses are needed to maintain protection. (4) Older adults or
those who are chronically ill are more susceptible to
vaccine-preventable diseases and to their complications. It is
particularly important to prevent inﬂuenza and pneumococcal
infections in subjects who might experience very serious
consequences and even fatalities as a result of their condition
of old age or already existing serious chronic diseases.
The demographics of industrialized countries, and of
countries in transition, explains an increasingly important
susceptibility to infectious diseases that particularly affects the
elderly. As a matter of fact, it is foreseen that in 2050, in
several European countries (for instance, Italy) the proportion
of the elderly (>65 years) will be about one-third of the total
population [6]. This means that a longer life expectation is
coupled with a progressive increase in the number of subjects
with an impairment of the immune system, which in turn
translates into an exponential increase of susceptibility to
diseases like pneumonia and herpes zoster.
However, not only are numbers of elderly in the population
changing. Also, the typical social proﬁle of today’s older adults
is different from yesterday’s. In the past, adults worked hard
until retirement, when their only remaining purpose was to
raise new generations, helping children to perform their duties,
and travelling only exceptionally. Care of older inﬁrm adults
was handled at home by relatives.
Today, we have an increasing number of people who remain
active until advanced age, who do more sports, travel very
frequently, live independently from new generations, and
demand more health services (including vaccinations able to
protect them and preserve their good health). However, in
contrast, the number of institutionalized elderly people is also
increasing, and the environment of such institutions may
increase the chances of transmission of certain diseases like
inﬂuenza and pneumococcal pneumonia.
Risk-based and Aged-based Recommenda-
tions
It is also worth noting that at least 80% of those aged
>65 years suffer from a condition of chronic illness that
indicates the need for the administration of certain vaccines
(i.e. inﬂuenza, pneumococcus). However, although there are
commendable exceptions, risk-based approaches to vaccine
administration usually fail (as demonstrated by experiences of
hepatitis A, hepatitis B, inﬂuenza) [7]. The reason for such
failures lies in the need to identify subjects with speciﬁc
diseases, that are often followed up by specialists rather than
by their general practitioners. Specialists should be fully
informed on vaccine characteristics and indications (which
very rarely occurs), and a clear decision on who should be
responsible for immunizing and registering vaccination should
be taken, which is again a hard-to-reach result. Age-based
vaccination strategies are not the solution to all problems, but
can substantially help to increase coverage in those above a
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certain age threshold. They allow easy access to the target
group, irrespective of the speciﬁc clinical condition, through an
infrastructure that either exists, or is easily constructible. A
possible added value of age-based vaccination strategies is the
opportunity to obtain a herd protection effect due to high
coverage in closed settings (such as, for instance, residential
homes for institutionalized patients), which would not be
possible with a risk-based-only strategy.
From a public health point of view, it is therefore more
feasible and less time- and resource-consuming to lower the
threshold age for active offer of certain vaccines, rather than
trying to ﬁnd each subject at risk selectively—a suggestive
comparison has been made with ﬁshing using a net rather than
a ﬁshing rod (M. Faccini, personal communication). Which, of
course, does not mean that we are allowed to stop our efforts
to reach every subject at risk of any age with recommended
vaccinations.
The recognition of the added value in terms of higher
coverage that can be reached in at-risk subjects, and the
evidence of indirect effects of mass vaccination on those who
suffer the worst consequences of the disease, are the reasons
for the progressive extension of inﬂuenza vaccination recom-
mendation in the USA, from the initial lowering to a population
>50 years, to the present day recommendation of use at all
ages (since 2010) [8]. The indirect effect of extending inﬂuenza
vaccination to school-aged children was demonstrated in
Japan, where disease incidence in the elderly decreased in the
years of universal immunization offer, but increased again when
the school programme was discontinued [9]. Similarly, an
age-based approach to pneumococcal vaccination using con-
jugate vaccines is likely to impact substantially more on
morbidity than a risk-based-only strategy, if a coverage similar
to that obtained with inﬂuenza can be foreseen [10]. Strepto-
coccus pneumoniae contributes to the overall morbidity due to
community-acquired pneumonia for more than two-thirds of
patients when we consider known aetiological agents [11]. In
some countries (like the USA), a high coverage with pneumo-
coccal vaccination in infancy caused a decrease in the incidence
of invasive pneumococcal diseases in the elderly as well,
through a clear herd protection effect [12]. However, an
impact on community-acquired pneumonia cases, although
possible, is probably not as relevant, because of the greater
amount of antibodies needed to prevent non-invasive pneu-
mococcal diseases compared with invasive ones [13]. For this
reason, an age-based plus risk-based approach to adult and
elderly pneumococcal vaccination seems advisable.
A third vaccination is needed in the elderly population, that
against herpes zoster and its most dreadful complication,
post-herpetic neuralgia, which can heavily impair the quality of
life of those affected (up to 12% of herpes zoster patients)
[14]. Also in this case, because risk factors are almost
impossible to predict, a single cohort or multiple cohorts
age-based approach seems to be the most suitable to protect
an aging population.
Vaccinations Needed due to Changing
Disease Epidemiology
Adults have become one of the most important targets for
vaccinations that were traditionally administered only to
infants or children. The maintenance in many countries for
several years of low coverage with the measles–mumps–
rubella vaccination has brought about a progressive increase of
susceptibility in adolescents and adults. This in turn has led to
outbreaks in adolescents and adults in general, and especially in
some settings, such as hospitals [15]. It is clear today that a
catch-up programme in adolescents and adults is an indispens-
able supplement to immunization of toddlers and children with
measles–mumps–rubella if elimination goals are to be reached
in Europe in the next few years. Susceptibility has also shifted
to older ages for hepatitis A, because of the progressive
improvement of environmental sanitation; therefore hepatitis
A has become an adult infection, not only of travellers [16], but
also of clients of exotic food restaurants. Pertussis has also
become a disease of adults, especially because immunity is not
lifelong, with consequent possibility of experiencing several
infections during life. In addition, infected adults can transmit
pertussis to infants, who are at risk of severe consequences.
This is the basis for the so-called ‘cocoon strategy’ aimed at
supplying protection to the newborn through the immunity of
parents and relatives [17].
Economic and Organizational Issues of
Adult Vaccinations
A complete evaluation of HTA aspects of adult vaccination is
needed to show that immunization is often cost-effective and
sometimes cost-saving for the healthcare system. An attempt
to assign scores in a semi-quantitative way to different
interventions (taking into account not only cost-effectiveness
ratios but also the total burden of disease avoided) showed
that not only childhood vaccination series, but also inﬂuenza
immunization of the elderly rank among the highest priority
interventions to be implemented [18]. In other words, the
belief that health promotion ‘is not worth it’ for older people
is out of date: as people live longer, there are more years for
older people to beneﬁt from health promotion/disease
prevention activities.
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The concept of ‘successful aging’ means that older people
no longer have to be willing to accept declines as the inevitable
consequence of age.
Conclusion
The future of vaccination is lifelong vaccination. To achieve
good uptake at all ages, we need to invest in communication
activities to show that vaccine-preventable diseases can occur
at any stage of life, and can be more serious in adults and the
elderly. Every country should ﬁnd different solutions (accord-
ing to the national healthcare system organization) to ﬁnance,
promote and administer all vaccines indicated at adult age.
Also, the economic convenience of such an approach should
be shown based on local studies. We must also be aware that
vaccination is more a global social process than an isolated
medical action, based on the notion of community good or
beneﬁt, the relationship between the individual and the
community, citizen and state, and health and disease.
Quoting the old physician Bartolomeo from Salerno (12th
century), today it is true that ′practical medicine is divided into
two parts: a science that preserves health, and one which
cures disease… To preserve health is a thing that can be done
better and with more certainty than restoring health once it
has been lost′.
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